Multiple functions of hypoxia-regulated miR-210 in cancer

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Qin, Qin ^a,b   Wei, Furong ^c   Li, Baosheng ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Diagnosis; Hypoxia; Metabolism; microRNA; miR 210; Prognosis; Proliferation

Indexed keywords

EPHRIN A3; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MICRORNA 210; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL INVASION; CELL PROLIFERATION; CELL PROTECTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC VALUE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MITOCHONDRIAL RESPIRATION; NEGATIVE FEEDBACK; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; REVIEW; SOLID TUMOR;

APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MITOCHONDRIA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 84902649752     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-50     Document Type: Review

References (108)

1. MicroRNAs: target recognition and regulatory functions. Bartel DP, Cell 2009 136 2 215 233 10.1016/j.cell.2009.01.002 19167326
2. The widespread regulation of microRNA biogenesis, function and decay. Krol J, Loedige I, Filipowicz W, Nat Rev Genet 2010 11 9 597 610 20661255
3. MicroRNA history: discovery, recent applications, and next frontiers. Almeida MI, Reis RM, Calin GA, Mutat Res 2011 717 1-2 1 8 21458467
4. Hypoxia in cancer: significance and impact on clinical outcome. Vaupel P, Mayer A, Cancer Metastasis Rev 2007 26 2 225 239 10.1007/s10555-007-9055-1 17440684 (Pubitemid 47101660)
5. Role of hypoxia in the hallmarks of human cancer. Ruan K, Song G, Ouyang G, J Cell Biochem 2009 107 6 1053 1062 10.1002/jcb.22214 19479945
6. Strategies to improve radiotherapy with targeted drugs. Begg AC, Stewart FA, Vens C, Nat Rev Cancer 2011 11 4 239 253 10.1038/nrc3007 21430696
7. A microRNA signature of hypoxia. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M, Mol Cell Biol 2007 27 5 1859 1867 10.1128/MCB.01395-06 17194750
8. Hypoxia response and microRNAs: no longer two separate worlds. Ivan M, Harris AL, Martelli F, Kulshreshtha R, J Cell Mol Med 2008 12 5A 1426 1431 10.1111/j.1582-4934.2008.00398.x 18624759
9. Emerging roles of microRNAs in the molecular responses to hypoxia. Crosby ME, Devlin CM, Glazer PM, Calin GA, Ivan M, Curr Pharm Des 2009 15 33 3861 3866 10.2174/138161209789649367 19925433
10. The role of hypoxia regulated microRNAs in cancer. McCormick R, Buffa FM, Ragoussis J, Harris AL, Curr Top Microbiol Immunol 2010 345 47 70 20549470
11. Hypoxia: a master regulator of microRNA biogenesis and activity. Nallamshetty S, Chan SY, Loscalzo J, Free Radic Biol Med 2013 64 20 30 23712003
12. HypoxamiRs and Cancer: From Biology to Targeted Therapy. Gee HE, Ivan C, Calin GA, Ivan M, Antioxid Redox Signal 2013
13. MicroRNA-210: a unique and pleiotropic hypoxamir. Chan SY, Loscalzo J, Cell Cycle 2010 9 6 1072 1083 10.4161/cc.9.6.11006 20237418
14. miR-210: More than a silent player in hypoxia. Devlin C, Greco S, Martelli F, Ivan M, IUBMB life 2011 63 2 94 100 21360638
15. miR-210: Fine-Tuning the Hypoxic Response. Ivan M, Huang X, Adv Exp Med Biol 2014 772 205 227 10.1007/978-1-4614-5915-6-10 24272361
16. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J, Clin Cancer Res 2008 14 5 1340 1348 10.1158/1078-0432.CCR-07-1755 18316553 (Pubitemid 351413913)
17. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL, Cancer 2010 116 9 2148 2158 20187102
18. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L, Cancer Biol Ther 2008 7 2 255 264 10.4161/cbt.7.2.5297 18059191 (Pubitemid 351590433)
19. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ, Mol Cell 2009 35 6 856 867 10.1016/j.molcel.2009.09. 006 19782034
20. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Kelly TJ, Souza AL, Clish CB, Puigserver P, Mol Cell Biol 2011 31 13 2696 2706 10.1128/MCB.01242-10 21555452
21. Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M, J Pathol 2011 224 2 280 288 10.1002/path.2860 21465485
22. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C, Cell Cycle 2009 8 17 2756 2768 10.4161/cc.8.17.9387 19652553
23. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE, Harris AL, Br J Cancer 2013 108 5 1133 1142 10.1038/bjc.2013.56 23449350
24. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H, Am J Physiol Heart Circ Physiol 2011 301 4 1519 1530 10.1152/ajpheart.01080.2010 21841015
25. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Takikawa T, Masamune A, Hamada S, Nakano E, Yoshida N, Shimosegawa T, Biochem Biophys Res Commun 2013 437 3 433 439 10.1016/j.bbrc.2013.06.097 23831622
26. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G, J Biol Chem 2011 286 1 420 428 10.1074/jbc.M110.170852 21044961
27. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Yang W, Sun T, Cao J, Liu F, Tian Y, Zhu W, Exp Cell Res 2012 318 8 944 954 10.1016/j.yexcr.2012.02.010 22387901
28. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Biswas S, Roy S, Banerjee J, Hussain SR, Khanna S, Meenakshisundaram G, Kuppusamy P, Friedman A, Sen CK, Proc Natl Acad Sci U S A 2010 107 15 6976 6981 10.1073/pnas.1001653107 20308562
29. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. He J, Wu J, Xu N, Xie W, Li M, Li J, Jiang Y, Yang BB, Zhang Y, Nucleic Acids Res 2013 41 1 498 508 10.1093/nar/gks995 23125370
30. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Kim JH, Park SG, Song SY, Kim JK, Sung JH, Cell Death Dis 2013 4 588 10.1038/cddis.2013.117 23579275
31. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. Kim HW, Haider HK, Jiang S, Ashraf M, J Biol Chem 2009 284 48 33161 33168 10.1074/jbc.M109.020925 19721136
32. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Gou D, Ramchandran R, Peng X, Yao L, Kang K, Sarkar J, Wang Z, Zhou G, Raj JU, Am J Physiol Lung Cell Mol Physiol 2012 303 8 682 691 10.1152/ajplung.00344.2011 22886504
33. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC, Circulation 2010 122 11 Suppl 124 131 20837903
34. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Chio CC, Lin JW, Cheng HA, Chiu WT, Wang YH, Wang JJ, Hsing CH, Chen RM, Arch Toxicol 2013 87 3 459 468 10.1007/s00204-012-0965-5 23108914
35. Neuroprotective effects of microRNA-210 against oxygen-glucose deprivation through inhibition of apoptosis in PC12 cells. Qiu J, Zhou XY, Zhou XG, Cheng R, Liu HY, Li Y, Mol Med Rep 2013 7 6 1955 1959 23591709
36. miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Wang F, Xiong L, Huang X, Zhao T, Wu LY, Liu ZH, Ding X, Liu S, Wu Y, Zhao Y, Wu K, Zhu LL, Fan M, Stem Cell Res 2013 11 1 657 667 10.1016/j.scr.2013.04.005 23688833
37. miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. Mizuno Y, Tokuzawa Y, Ninomiya Y, Yagi K, Yatsuka-Kanesaki Y, Suda T, Fukuda T, Katagiri T, Kondoh Y, Amemiya T, Tashiro H, Okazaki Y, FEBS Lett 2009 583 13 2263 2268 10.1016/j.febslet.2009.06.006 19520079
38. Hypoxia-inducible factor 1-alpha induces miR-210 in normoxic differentiating myoblasts. Cicchillitti L, Di Stefano V, Isaia E, Crimaldi L, Fasanaro P, Ambrosino V, Antonini A, Capogrossi MC, Gaetano C, Piaggio G, Martelli F, J Biol Chem 2012 287 53 44761 44771 10.1074/jbc.M112.421255 23148210
39. MicroRNA expression signature for Satb2-induced osteogenic differentiation in bone marrow stromal cells. Gong Y, Xu F, Zhang L, Qian Y, Chen J, Huang H, Yu Y, Mol Cell Biochem 2014 387 227 239 10.1007/s11010-013- 1888-z 24218084
40. Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Sarakul O, Vattanaviboon P, Tanaka Y, Fucharoen S, Abe Y, Svasti S, Umemura T, Blood Cells Mol Dis 2013 51 2 98 103 10.1016/j.bcmd.2013.03.005 23623309
41. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F, J Biol Chem 2008 283 23 15878 15883 10.1074/jbc.M800731200 18417479
42. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, Yao M, Li J, He X, Hepatology 2011 54 6 2064 2075 10.1002/hep.24614 22144109
43. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. Alaiti MA, Ishikawa M, Masuda H, Simon DI, Jain MK, Asahara T, Costa MA, J Cell Mol Med 2012 16 10 2413 2421 10.1111/j.1582-4934.2012.01557.x 22360314
44. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM, Busund LT, PLoS One 2012 7 1 29671 10.1371/journal.pone.0029671 22295063
45. Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Liu F, Lou YL, Wu J, Ruan QF, Xie A, Guo F, Cui SP, Deng ZF, Wang Y, Kidney Blood Press Res 2012 35 3 182 191 10.1159/000331054 22123256
46. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Lou YL, Guo F, Liu F, Gao FL, Zhang PQ, Niu X, Guo SC, Yin JH, Wang Y, Deng ZF, Mol Cell Biochem 2012 370 1-2 45 51 22833359
47. The effect of intra-articular injection of microRNA-210 on ligament healing in a rat model. Shoji T, Nakasa T, Yamasaki K, Kodama A, Miyaki S, Niimoto T, Okuhara A, Kamei N, Adachi N, Ochi M, Am J Sports Med 2012 40 11 2470 2478 10.1177/0363546512458894 22986296
48. Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. Yamasaki K, Nakasa T, Miyaki S, Yamasaki T, Yasunaga Y, Ochi M, J Orthop Res 2012 30 8 1263 1270 10.1002/jor.22079 22287106
49. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T, J Biol Chem 2013 288 15 10849 10859 10.1074/jbc.M112.446831 23439645
50. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH, J Biol Chem 2013 288 48 34343 34351 10.1074/jbc.M113.480822 24133215
51. MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. Zeng L, He X, Wang Y, Tang Y, Zheng C, Cai H, Liu J, Wang Y, Fu Y, Yang GY, Gene Ther 2014 21 37 43 10.1038/gt.2013.55 24152581
52. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J, Cell Metab 2009 10 4 273 284 10.1016/j.cmet.2009.08.015 19808020
53. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Chen Z, Li Y, Zhang H, Huang P, Luthra R, Oncogene 2010 29 30 4362 4368 10.1038/onc.2010.193 20498629
54. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, Ragoussis J, Harris AL, PLoS One 2010 5 4 10345 10.1371/journal.pone.0010345 20436681
55. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci JE, Pouysségur J, Gounon P, Hofman P, Barbry P, Mari B, Cell Death Differ 2011 18 3 465 478 10.1038/cdd.2010.119 20885442
56. Suppression of mitochondrial electron transport chain function in the hypoxic human placenta: a role for miRNA-210 and protein synthesis inhibition. Colleoni F, Padmanabhan N, Yung HW, Watson ED, Cetin I, van Patot MC T, Burton GJ, Murray AJ, PLoS One 2013 8 1 55194 10.1371/journal.pone.0055194 23383105
57. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM, Mari B, Cell Death Dis 2013 4 544 10.1038/cddis.2013.71 23492775
58. microRNAs target identification: lessons from hypoxamiRs. Bertero T, Robbe-Sermesant K, Le Brigand K, Ponzio G, Pottier N, Rezzonico R, Mazure NM, Barbry P, Mari B, Antioxid Redox Signal 2013
59. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
60. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, Gui Y, Cai Z, PLoS One 2012 7 12 52280 10.1371/journal.pone.0052280 23284967
61. ROD1 is a seedless target gene of hypoxia-induced miR-210. Fasanaro P, Romani S, Voellenkle C, Maimone B, Capogrossi MC, Martelli F, PLoS One 2012 7 9 44651 10.1371/journal.pone.0044651 23024754
62. Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Yang W, Wei J, Sun T, Liu F, Radiat Oncol 2013 8 102 10.1186/1748-717X-8-102 23618526
63. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y, PLoS One 2006 1 116 10.1371/journal.pone.0000116 17205120
64. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S, FEBS Lett 2008 582 16 2397 2401 10.1016/j.febslet.2008.05.048 18539147
65. Regulation of the cellular DNA double-strand break response. Cann KL, Hicks GG, Biochem Cell Biol 2007 85 6 663 674 10.1139/O07-135 18059525 (Pubitemid 351198414)
66. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM, Cancer Res 2009 69 3 1221 1229 10.1158/0008-5472.CAN-08-2516 19141645
67. MicroRNAs in immune regulation-opportunities for cancer immunotherapy. Okada H, Kohanbash G, Lotze MT, Int J Biochem Cell Biol 2010 42 8 1256 1261 10.1016/j.biocel.2010.02.002 20144731
68. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S, Cancer Res 2012 72 18 4629 4641 10.1158/0008-5472.CAN-12-1383 22962263
69. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Denko NC, Nat Rev Cancer 2008 8 9 705 713 10.1038/nrc2468 19143055
70. Targeting glucose metabolism in patients with cancer. Elf SE, Chen J, Cancer 2014 120 774 780 10.1002/cncr.28501 24374503
71. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR, Nature 2005 435 7043 834 838 10.1038/nature03702 15944708 (Pubitemid 40839735)
72. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G, Proc Natl Acad Sci U S A 2011 108 9 3713 3718 10.1073/pnas.1100048108 21300873
73. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chery L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M, PLoS One 2013 8 7 69239 10.1371/journal.pone.0069239 23935962
74. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC, Cancer Cell 2006 9 3 189 198 10.1016/j.ccr.2006.01.025 16530703 (Pubitemid 43357945)
75. Accurate molecular classification of renal tumors using microRNA expression. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, Avivi C, Rosenblatt K, Polak-Charcon S, Ramon J, Rosenfeld N, Spector Y, J Mol Diagn 2010 12 5 687 696 10.2353/jmoldx.2010. 090187 20595629
76. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F, Int J Immunopathol Pharmacol 2010 23 4 1229 1234 21244772
77. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I, Rolland D, Salon C, Godfraind C, DeFraipont F, Dhobb M, Pelletier L, Wion D, Gay E, Berger F, Issartel JP, PLoS One 2011 6 5 20600 10.1371/journal.pone.0020600 21655185
78. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN, Cell Cycle 2011 10 3 507 517 10.4161/cc.10.3.14754 21270527
79. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y, Yamashita H, Jpn J Clin Oncol 2012 42 4 256 263 10.1093/jjco/hys001 22323552
80. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C, PLoS One 2011 6 6 20980 10.1371/journal.pone.0020980 21738599
81. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S, Cancer Prev Res (Phila) 2009 2 9 807 813 10.1158/1940-6207.CAPR-09-0094 19723895
82. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H, Int J Cancer 2010 126 1 73 80 10.1002/ijc.24687 19551852
83. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D, Pancreas 2013 42 1 67 71 10.1097/MPA.0b013e3182592ba7 22850622
84. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Cho WC, Chow AS, Au JS, Eur J Cancer 2009 45 12 2197 2206 10.1016/j.ejca.2009. 04.039 19493678
85. Differentially expressed microRNAs in small cell lung cancer. Miko E, Czimmerer Z, Csanky E, Boros G, Buslig J, Dezso B, Scholtz B, Exp Lung Res 2009 35 8 646 664 10.3109/01902140902822312 19895320
86. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Xing L, Todd NW, Yu L, Fang H, Jiang F, Mod Pathol 2010 23 8 1157 1164 10.1038/modpathol.2010.111 20526284
87. Positive prognostic impact of miR-210 in non-small cell lung cancer. Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT, Bremnes RM, Lung Cancer 2014 83 272 278 10.1016/j.lungcan.2013.11.005 24305009
88. The VHL-dependent regulation of microRNAs in renal cancer. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM, BMC Med 2010 8 64 10.1186/1741-7015-8-64 20964835
89. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O, Tumour Biol 2013 34 1 481 491 10.1007/s13277-012-0573-2 23150176
90. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL, Br J Haematol 2008 141 5 672 675 10.1111/j.1365-2141.2008.07077.x 18318758 (Pubitemid 351667616)
91. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Cai H, Lin L, Cai H, Tang M, Wang Z, Med Oncol 2013 30 2 499 23430441
92. Differential expression of miRNAs in esophageal cancer tissue. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC, Wu XN, Oncol Lett 2013 5 5 1639 1642 23761828
93. miRNA profiling along tumour progression in ovarian carcinoma. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R, J Cell Mol Med 2011 15 7 1593 1602 10.1111/j.1582-4934.2010.01148.x 20716115
94. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M, Jiang F, BMC Cancer 2011 11 374 10.1186/1471-2407-11-374 21864403
95. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J, Clin Cancer Res 2011 17 21 6802 6811 10.1158/1078-0432.CCR-11-0419 21890451
96. Differential signature of fecal microRNAs in patients with pancreatic cancer. Ren Y, Gao J, Liu JQ, Wang XW, Gu JJ, Huang HJ, Gong YF, Li ZS, Mol Med Rep 2012 6 1 201 209 22504911
97. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F, J Cancer Res Clin Oncol 2014 140 145 150 10.1007/s00432-013-1555-5 24281335
98. Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB, Shao GG, J Int Med Res 2013 41 5 1437 1444 10.1177/0300060513497560 24065453
99. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Zhao A, Li G, Peoc'h M, Genin C, Gigante M, Exp Mol Pathol 2013 94 1 115 120 10.1016/j.yexmp.2012.10.005 23064048
100. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A, Int J Oncol 2014 44 1 53 58 24212760
101. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, Jung K, Clin Chem 2010 56 6 998 1006 10.1373/clinchem.2009. 141580 20378769
102. Circulating microRNAs as stable blood-based markers for cancer detection. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M, Proc Natl Acad Sci U S A 2008 105 30 10513 10518 10.1073/pnas.0804549105 18663219
103. Circulating microRNAs in cancer: origin, function and application. Ma R, Jiang T, Kang X, J Exp Clin Cancer Res 2012 31 38 10.1186/1756-9966-31-38 22546315
104. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW, Taubert H, Int J Cancer 2012 130 5 1230 1235 10.1002/ijc.26109 21455991
105. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM, Proc Natl Acad Sci U S A 2012 109 8 3024 3029 10.1073/pnas.1200010109 22315424
106. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y, J Transl Med 2013 11 10 10.1186/1479-5876-11-10 23302469
107. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J, Cancer Res 2011 71 17 5635 5645 10.1158/0008-5472.CAN-11-0489 21737487
108. Regulation of proliferation-survival decisions during tumor cell hypoxia. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE, Mol Cell Biol 1998 18 5 2845 2854 9566903 (Pubitemid 28183453)